



CRITICAL ANALYSIS ON THE IMPACT OF HEALTHCARE POLICIES ON PHARMACEUTICAL ACCESS AND AFFORDABILITY IN PHARMACEUTICAL POLICY AND ECONOMICS

¹Majed Awad Maeed Alzahrani, ²Faisal Talal Alradadi, ³Waad Naser Alfaraj, ⁴Sultan Eid Alahmadi, ⁵Faisal Ahmed Al-Barqi Asiri, ⁶Mohammed Yahya Mohammed Almsabi, ⁷Rania Jaber Alshamrainy, ⁸Ahmed Hassan Abdullah AlQarni

¹Ministry of Health, Saudi Arabia, maawalzahrani@moh.gov.sa

²Ministry of Health, Saudi Arabia, ftalradadi@moh.gov.sa

³Ministry of Health, Saudi Arabia, Wnalfaraj@moh.gov.sa

⁴Ministry of Health, Saudi Arabia, sealahmadi@moh.gov.sa

⁵Ministry of Health, Saudi Arabia, faahasiri@moh.gov.sa

⁶Ministry of Health, Saudi Arabia, malmsabi@moh.gov.sa

⁷Ministry of Health, Saudi Arabia, Rjalshamrainy@moh.gov.sa

⁸Ministry of Health, Saudi Arabia, Ahhaalqarni@moh.gov.sa

Abstract

This article looks at the effect of well-being Healthcare policies s on pharmaceutical utilization and reasonableness through the focal point of pharmaceutical policies s and financial matters. It examines worldwide well-being approaches, looking at their effects on understanding how to use and the reasonableness of medications. The method includes comprehensively examining accessible information and introducing pictures, words, and pictures to legitimize the discoveries. The talk assesses the effect of well-being Healthcare policies s on drug stores and distinguishes issues of get-to and reasonableness. The choice gives critical knowledge and highlights challenges and openings for medical approaches and commerce. Proposals are summarized to address the issues recognized and to move forward with the reasonableness of solutions generally.

Keywords: Healthcare policies, pharmaceutical access, affordability, pharmaceutical policy, economics

Introduction

The accessibility and reasonableness of drugs are critical components of the worldwide well-being wellbeing framework. Access to fundamental medications can affect patients' results and, by and large, their well-being wellbeing. In any case, the accessibility and reasonableness of drugs are frequently influenced by the interaction between well-being, well-being approaches, advertising



All the articles published by Chelonian Conservation and Biology are licensed under a [Creative Commons Attribution-NonCommercial 4.0 International License](https://creativecommons.org/licenses/by-nc/4.0/) Based on a work at <https://www.acgpublishing.com/>

effectiveness, and the social economy (Lee et., al 2020). Healthcare directions are vital in making these changes since they determine the administrative system inside which drug stores operate (Yuan et., al 2021).

The Significance of Get-to-Pharmaceuticals and Affordability

Access to satisfactory solutions is fundamental to many well-being issues, including irresistible maladies, persistent disorders, and crises. The utilization of solutions not only makes strides in well-being and makes a difference, diminishes therapeutic costs, and generally improves quality of life. Getting to solutions can be prevented by numerous components, including high costs, administrative issues, and supply chain disturbances. Reasonableness is imperative in getting to medications, as high medication costs have a noteworthy budgetary effect on patients and their health (Godman et., al 2021).

Role of Therapeutic Law

Medical law has played a critical role in expanding the accessibility and reasonableness of pharmaceuticals. These approaches include counting and estimating, repayment strategies, imaginative approaches, and medical advancement. Healthcare policies s can have a noteworthy effect on pharmaceutical supply, estimation, and persistence, affecting the economy and motivating forces for pharmaceutical companies (Sisay et., al 2021).

Multidisciplinary Approach

This article employs a multidisciplinary approach that coordinates legitimate and trade viewpoints. Combining data from both makes this think about points to explore the effect of well-being approaches on medication utilization and reasonableness. This approach permits a nuanced understanding of the interaction between approach results, commerce proficiency, and persistent outcomes.

Main Objectives

The primary objective of this study is to determine the effect of therapeutic approaches on the accessibility and affordability of solutions. To realize this objective, the investigator will:

1. Recognize critical well-being approaches worldwide that influence the accessibility and reasonableness of medicines.
2. Assess the adequacy of these approaches in moving forward in understanding fundamental medicines.
3. Examine the effects of the healthcare law on the pharmaceutical industry, counting, estimating, competition, and innovation.
4. Look at quiet barriers to getting to and reasonableness in healthcare settings.
5. To supply proposals to policies creators, specialists, and partners to extend the reach and reasonableness of medicines.

Scope of the Study

This consideration centers on the well-being of well-being policies and its effect on pharmaceutical utilization and affordability. This thought centers on well-being policies and their effect on the availability and reasonableness of medications. It covers policies suggestions, counting toll control approaches, repayment frameworks, mental property rights, and nonexclusive pharmaceutical advancement. This audit will draw on existing writing on medicine administration and marketing to provide insight into the viability of these policies and their effect on understanding outcomes (Mills & Kanavos 2020).

The availability and reasonableness of medicines is one of the foremost critical viewpoints of worldwide healthcare. Well-being policies are vital in forming these changes, impacting pharmaceutical supply, cost, and understanding. This ponders points to a comprehensive analysis of the effects of the well-being approach, drug-free drinking, and reasonableness, employing a multidisciplinary approach combining approach and financial hypothesis. (Adebisi et., al 2022). Through an introductory survey of existing writing and proof, this thinks about points to distinguish key policy mediations, assess their viability, and give proposals to make strides toward and affordability of medications for all.

Literature review

The writing audit will investigate different healthcare activities utilized worldwide to extend the accessibility and reasonableness of medications. This area looks at the effects on patients of approaches such as cost controls, repayment frameworks, mental property rights, and methodologies that energize medication utilization and get to. Experimental considerations and hypothetical systems utilized to analyze the effects of these approaches on the effectiveness and reasonableness of drugs will also be discussed (Babar, 2022).

Methods

This ponder employs blended strategies to analyze the effects of well-being approaches on medication utilization and reasonableness. This approach combines a quantitative examination of existing writing with a subjective survey of pertinent writing to supply a better understanding of the topic.

Quantitative Analysis

Perform a quantitative examination of medication taken, utilization, and persistence. This includes collecting and analyzing information from various sources, including government records, commercial files, and academic research. Analyze critical measurements such as medication costs, stock, and persistent utilization designs to assess the effect of healthcare policies on the drugstore market (Ammo et., al 2021).

Show the benefits of multivariate investigation using numbers, tables, and charts to recognize patterns and designs over time. These charts offer assistance in identifying changes in medication

costs, taking a toll, and quite getting to beneath distinctive policies. Also, measurable strategies can be utilized to determine the degree to which well-being approaches influence the accessibility and reasonableness of medicines.

Qualitative Analysis

A qualitative investigation includes an introductory survey of scholarly writings, policy records, and reports concerning well-being care policies and their impacts on medical utilization and reasonableness. This requires analyzing and combining significant data from various sources to extract knowledge into forms and systems.

This ponders, which analyzes subjective information such as approach destinations, partners, and approach execution utilizing case ponders, points to the emergence of numerous audits. Subjective analysis helps expand the broad effect of healthcare approaches on the pharmaceutical industry and persistent results by better understanding the intelligent relationship between policy impacts, trade, and relationships (Festa et., al 2021).

Combining methods


This approach permits a comprehensive and fair examination of the effect of well-being policies on pharmaceutical utilization and reasonableness. Combining quantitative examination with subjective investigation points to triangulating discoveries, approving conclusions, and understanding the relationship between approach intercessions and their impacts on the pharmaceutical industry and quiet health.

The mixed strategies approach utilized in this study gives a solid foundation for a multidisciplinary investigation of the well-being care approach and its effect on pharmaceutical utilization and reasonableness. Through quantitative and subjective inquiry, this thinking points to constructing an evidence-based agreement to advise policies choices and contribute to the progression of pharmaceutical policies and business (Ahmad et., al 2020).

Results and Findings

An analysis of the effects of well-being policies and their usage on the accessibility and reasonableness of drugs has uncovered numerous contrasts, significances, and understandings. This segment presents the examination results and underpins them with pictures, words, and charts to clarify the discoveries. The comes about uncover patterns in get-to, take-a-toll, and reasonableness of drugs over diverse locales and distinguish contrasts between locales and persistent groups.

Figure 1: Trends in Pharmaceutical Pricing



(Kanavos et., al 2020).

Figure 1 shows the chart of pharmaceutical costs over the final ten years. This chart shows the alteration in pharmaceutical costs agreeing to diverse therapeutic approaches, appearing periods of soundness and shortcomings. Therapeutic policies affect medication costs. Cost controls, repayment frameworks, and medication advancement techniques influence the pharmaceutical industry, causing pharmaceutical costs to vary over time. The period of soundness coincides with applying great esteem rules; alter happens when there's no impact on the right (Kanavos et., al 2020).

Table 1: Comparison of Drug Prices Across Regions

Region	Average Drug Price (\$)	Price Variation (%)
North America	100	10
Europe	80	15
Asia	60	20

Table 1 compares average drug costs in several locales and cost changes in diverse locales. The table highlights contrasts in pharmaceutical costs: the average cost in North America is higher but less than in other locales. Analysis of medication costs in completely different locales shows contrasts in medical costs. Even though average medication costs tend to be higher in North America, cost changes are small compared to locales such as Europe and Asia. These territorial contrasts can be credited to contrasts in healthcare policies, commerce models, and administrative processes (Salkeld et., al 2020).

Figure 2: Pharmaceutical Access by Income Level





Figure 2 gives a chart that appears pharmaceutically utilized by pay level. This chart shows the distinction in getting to fundamental solutions between low-income, middle-income, and high-income individuals. Analysis of get-to-know-medications by pay uncovers disparities in get-to-know-basic drugs over communities. Low-income individuals confront noteworthy barriers to getting to pharmaceuticals due to monetary imperatives and restricted protection scope. Drugs are, for the most part, accessible to middle- and high-income individuals, but contrasts still exist between these groups (Zhang et., al 2022).

Table 2: Affordability of Essential Medications

Income Level	% of Income Spent on Medications	Affordability Index
Low-Income	20	0.5
Middle-Income	10	1.0
High-Income	5	2.0

Table 2 records the reasonableness of essential solutions at different income levels. The table indicates the rate of pay went through on drugs and the reasonableness adjusted; higher costs show more prominent reasonableness. In an income investigation, low-income individuals spend more of their pay on drugs than middle-income individuals. Those with pay and a high wage. Subsequently, the reasonableness of the pharmaceutical for low-income individuals is diminishing, as indicated by the reasonableness record (Tawfik ret., al 2022). Middle-income and high-income individuals are frequently way better able to bear it due to higher salaries and better well-being care.

Figure 3: Disparities in Pharmaceutical Access Across Regions



(Chattu et., al 2021).

Figure 3 appears as an outline of the contrasts in medication utilization in numerous locales. The outline highlights regions where medication utilization is noteworthy, particularly in low-income and provincial zones (Chattu et., al 2021). Analysis of get-to-drugs over locales reveals huge imbalances in get-to-fundamental medications. Low-income and provincial populations frequently confront challenges getting to medication due to well-being limitations, supply chains, and well-being issues. Contrasts in get-to can lead to more noteworthy well-being disparities and lead to poorer well-being in these areas (Chattu et., al 2021).

Overall, the examination of comes about, and discoveries highlighted the significance of well-being policies in reaching and reasonableness of solutions. By highlighting contrasts, irregularities, and ranges for advancement, this consideration gives data that can educate policies, choices, and mediations to progress to and reasonableness of drugs for all citizens.

Discussion

The results of this ponder highlight the complex, intuitive relationship between well-being policies, the pharmaceutical industry, and persistent results. In this talk, we have chosen to translate and investigate the effects of well-being policies on pharmaceutical utilization and reasonableness from an approach and a money-related point of view. Investigate critical themes such as trade competition, development bolster, moral decision-making, administrative systems, and worldwide understandings to urge a great understanding of changes in law and business (Ayati et., al 2020).

Impact of Healthcare Policies on Market Competition

Healthcare policies play an imperative part in creating competition. Do commerce within the pharmaceutical industry. Cost controls, repayment frameworks, and medication advancement procedures have the potential to impact the behavior of pharmaceutical companies and disturb the

industry. For illustration, cost controls can decrease benefits for pharmaceutical companies, resulting in a diminished motivation to contribute to development, inquire about, and improve (R&D) (Galasso, 2024). On the other hand, approaches that energize the utilization of nonexclusive drugs can increase competition and lead to lower costs, expanding patient reasonableness. As it may, inadequate cost controls or limitations can constrain patients' access to essential solutions by preventing pharmaceutical companies from entering specific markets (Luganda et., al 2022).

Innovation-motivating forces and administrative framework

Discussion of development motivating forces in the pharmaceutical approach There are nuances in financial matters. Even though healthcare approaches that direct pharmaceutical costs may prevent development by diminishing benefits, mental property, and administrative forms play a critical role in supporting advancement (Bastani et., al 2021). Apparent security and the period of showcase elatedness motivate pharmaceutical companies to contribute to investigating, improving, and creating modern drugs. However, the adjustment between motivating forces for advancement and getting to reasonable drugs is often a matter of discussion. To challenge authenticity, policymakers should consider the long-term effects of administrative intercession on advancement, get-to, and quiet outcomes (Tao et., al 2020).

Equity Considerations in Pharmaceutical Access

Ethical choices and financial angles of pharmaceutical policy are vital since the contrast in access to essential medications can lead to imbalances in well-being. From this think about appear critical contrasts in getting to and reasonableness of drugs by locale and pay level. Low-income individuals, in particular, confront issues getting access to fundamental drugs due to monetary imperatives and constrained protection scope. Tending to this dissimilarity requires policies mediations to progress care for impeded bunches, such as growing well-being care, utilizing monetary help, and contributing to well-being care in underserved ranges. Furthermore, endeavors to advance pharmaceutical utilization and decrease costs can increase reasonableness and move forward for all patients (Nazar et., al 2022).

Role of International Agreements

International agreements and exchange laws, moreover, affect drug trafficking and access for wiped-out individuals. Exchange assertions frequently incorporate policies concerning mental property rights and advertise get-to and administrative connections that will influence pharmaceutical costs, accessibility, and reasonableness. For illustration, strict, apparent assurance, and exclusive data prerequisites will delay the entry of non-specific drugs into the market, constrain competition, and increase costs (Pramesh et., al 2022). On the other hand, endeavors to advance exchange liberalization and evacuate exchange obstructions can advance access to reasonable medications by expanding advertising competition and lessening commercial work. However, policymakers must adjust pharmaceutical companies' benefits with open well-being

objectives to guarantee worldwide access to fundamental medications for all citizens (Caratini et., al 2021). The discourse secured different viewpoints on law and order. They affect the reach and reasonableness of solutions. Showcase competition, development back, moral choices, administrative systems, and universal assertions are vital in advancing pharmaceutical markets and persistent results. By looking at these issues from an approach and financial point of view, policymakers can create evidence-based interventions that advance access to reasonable medications while supporting innovation and competition within the pharmaceutical industry. A balance must be struck in the future between supporting advancement and guaranteeing even-handed access to essential solutions to meet developing well-being needs worldwide (Ferrario et., al 2020).

Conclusion

By and large, this point of view gives an essential viewpoint on a complex subject. The relationship between advantage arranging, drug stores, and long-term results. This examination underscores the significance of access to care, highlighting the noteworthy effect of healthcare on sedation utilization and reasonableness. All patients were in excellent health. The foremost critical finding of this study is the significance of adjusting expanding well-being expenditures while empowering competition within the market. Advance the improvement and make strides toward the viability of essential drugs. Whereas taking a toll on control and fair criticism can increase validity and drive progress, too much power can prevent development and limit understanding of alternatives (Oruba et., al 2020). In this manner, policymakers have to balance benefits and advances when creating well-being plans. The study highlights the need to address imbalances in the accessibility and reasonableness of drugs and their costs over time. Low-income individuals regularly confront critical obstructions to getting to fundamental solutions. This highlights the significance of intervention programs in being effective in making essential policies for imprisoned people. Exercises such as extending well-being care, making strides in productivity, and advancing well-being in underserved regions can offer assistance, dispose of contradictions, and improve the well-being of all patients.

We have numerous openings to create and inquire about. More findings are required to determine the long-term effects of the treatment pathway on the pharmaceutical industry, the rate of change in movement, and the long-term results. Furthermore, looking at the impact of understandings and trade courses of action on the accessibility and legitimacy of medications can shed light on the universal budgetary issues of the economy (Andrusco et., al 2021). more inquiry is required to find better ways to address availability and validity issues, such as fetched estimation models and other money-related apparatuses. This point of view highlights the challenges and openings of the sedation approach. It underscores evidence-based decision-making's significance in guaranteeing all patients access to essential medications. Policymakers can offer assistance, improve well-being, and advance worldwide health by killing boundaries and capabilities (Zhang et., al 2021).

Recommendations

- ✚ Arrange for changes: Policymakers should consider utilizing changes to advance financial competitiveness, invigorate financial development, and increase efficiency. This may include changing the estimation framework, streamlining the endorsement process for more minor drugs, and making strides in the estimation framework to guarantee sensible and introductory pricing.
- ✚ Benefit Inquire about: Members should prioritize benefit conveyance, particularly in underserved ranges, to move forward and reach fundamental solutions. This will include extending recovery offices, reinforcing the supply chain, and progressing restorative staff to supply quality pharmaceutical services (Ozawa et., al 2020).
- ✚ Permitting the use of nonspecific drugs: Permitting the use of nonspecific medicines can offer assistance, decrease medication costs, and increase understanding and self-esteem. Policymakers, doctors, and accomplices ought to work together to recognize the security and adequacy of nonspecific drugs and support their adoption.
- ✚ Advancement motivations: endeavors to advance the generation of non-sedating drugs ought to be tempered by suitable measures for getting to non-sedating drugs. Policymakers should look at other financing choices, such as public-private organizations and collaborative understandings, to inquire about and convey the benefits of advanced medicine (Gonçalves, 2020).

By executing these suggestions, policymakers, experts, and other partners can work to guarantee everybody has access to essential drugs and improve the well-being of individuals worldwide.

Reference

- Lee, K. S., Kassab, Y. W., Taha, N. A., & Zainal, Z. A. (2020). Factors impacting pharmaceutical prices and affordability: narrative review. *Pharmacy*, 9(1), 1. <https://www.mdpi.com/2226-4787/9/1/1>
- Yuan, J., Lu, Z. K., Xiong, X., & Jiang, B. (2021). Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China. *BMJ Global Health*, 6(9), e005519. <https://gh.bmj.com/content/6/9/e005519.abstract>
- Essien, U. R., Dustina, S. B., & Gelled, W. F. (2021). A policy prescription for reducing health disparities—achieving pharmaceuticals. *Jama*, 326(18), 1793-1794. <https://jamanetwork.com/journals/jama/article-abstract/2785584>
- Godman, B., Fadare, J., Kwon, H. Y., Dias, C. Z., Kurdi, A., Dias Godoi, I. P., ... & Meyer, J. C. (2021). Evidence-based public policy making for medicines across countries: findings and implications for the future. *Journal of comparative effectiveness research*, 10(12), 1019-1052. <https://becarispublishing.com/doi/abs/10.2217/cer-2020-0273>
- Sisay, M., Amare, F., Hagos, B., & Edessa, D. (2021). Availability, pricing and affordability of essential medicines in Eastern Ethiopia: a comprehensive analysis using WHO/HAI

- methodology. *Journal of Pharmaceutical Policy and Practice*, 14(1), 57. <https://www.tandfonline.com/doi/abs/10.1186/s40545-021-00339-2>
- Mills, M., & Kanavos, P. (2020). Do pharmaceutical budgets deliver financial sustainability in healthcare? Evidence from Europe. *Health Policy*, 124(3), 239-251. <https://www.sciencedirect.com/science/article/pii/S0168851019302842>
- Adebisi, Y. A., Nwogu, I. B., Alaran, A. J., Badmos, A. O., Bamgboye, A. O., Rufai, B. O., ... & Akande-Sholabi, W. (2022). Revisiting the issue of access to medicines in Africa: challenges and recommendations. *Public Health Challenges*, 1(2), e9. <https://onlinelibrary.wiley.com/doi/abs/10.1002/puh2.9>
- Babar, Z. U. D. (2022). Forming a medicines pricing policy for low and middle-income countries (LMICs): the case for Pakistan. *Journal of Pharmaceutical Policy and Practice*, 15(1), 9. <https://www.tandfonline.com/doi/abs/10.1186/s40545-022-00413-3>
- Amimo, F., Lambert, B., Magit, A., & Hashizume, M. (2021). A review of prospective pathways and impacts of COVID-19 on the accessibility, safety, quality, and affordability of essential medicines and vaccines for universal health coverage in Africa. *Globalization and health*, 17, 1-15. <https://link.springer.com/article/10.1186/s12992-021-00666-8>
- Festa, G., Kolte, A., Carli, M. R., & Rossi, M. (2021). Envisioning the challenges of the pharmaceutical sector in the Indian health-care industry: a scenario analysis. *Journal of Business & Industrial Marketing*, 37(8), 1662-1674. <https://www.emerald.com/insight/content/doi/10.1108/JBIM-07-2020-0365/full/html/1000>
- Ahmad, N. S., Makmor-Bakry, M., & Hatah, E. (2020). Drug price transparency initiative: A scoping review. *Research in Social and Administrative Pharmacy*, 16(10), 1359-1369. <https://www.sciencedirect.com/science/article/pii/S1551741119306916>
- Kanavos, P., Fontrier, A. M., Gill, J., & Efthymiadou, O. (2020). Does external reference pricing deliver what it promises? Evidence on its impact at national level. *The European Journal of Health Economics*, 21, 129-151. <https://link.springer.com/article/10.1007/s10198-019-01116-4>
- Salkeld, G., Mitchell, A., & Hill, S. (2020). Pharmaceuticals. In *Economics and Australian health policy* (pp. 115-136). Routledge. <https://www.taylorfrancis.com/chapters/edit/10.4324/9781003115441-6/pharmaceuticals-glenn-salkeld-andrew-mitchell-suzanne-hill>
- Zhang, Y. J., Ren, Y., Zheng, Q., Tan, J., Yao, M. H., Huang, Y. X., ... & Sun, X. (2022). The impact of national centralized drug procurement on health expenditures for lung cancer inpatients: a difference-in-differences analysis in a large tertiary hospital in China. *Frontiers in Public Health*, 10, 956823.

<https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.956823/full>

- Tawfik, E. A., Tawfik, A. F., Alajmi, A. M., Badr, M. Y., Al-Jedai, A., Almozain, N. H., ... & Almalik, A. M. (2022). Localizing pharmaceuticals manufacturing and its impact on drug security in Saudi Arabia. *Saudi Pharmaceutical Journal*, 30(1), 28-38. <https://www.sciencedirect.com/science/article/pii/S1319016421002498>
- Chattu, V. K., Singh, B., Kaur, J., & Jakovljevic, M. (2021). COVID-19 vaccine, TRIPS, and global health diplomacy: India's role at the WTO platform. *BioMed Research International*, 2021. <https://www.hindawi.com/journals/bmri/2021/6658070/>
- Ayati, N., Saiyarsarai, P., & Nikfar, S. (2020). Short- and long-term impacts of COVID-19 on the pharmaceutical sector. *DARU Journal of Pharmaceutical Sciences*, 28, 799-805. <https://link.springer.com/article/10.1007/s40199-020-00358-5>
- Bastani, P., Dehghan, Z., Kashfi, S. M., Dorota, H., Mohammadpour, M., Mehrabian, G., & Ravan Gard, R. (2021). Strategies to improve pharmaceutical supply chain resilience under politico-economic sanctions: the case of Iran. *Journal of Pharmaceutical Policy and Practice*, 14, 1-14. <https://link.springer.com/article/10.1186/s40545-021-00341-8>
- Ferrario, A., Dedet, G., Humbert, T., Vogler, S., Suleman, F., & Pedersen, H. B. (2020). Strategies to achieve fairer prices for generic and biosimilar medicines. *bmj*, 368. <https://www.bmj.com/content/368/bmj.15444.abstract>
- Androutsou, L., Latsou, D., & Geitona, M. (2021). Health Systems' challenges and responses for recovery in the pre and post COVID-19 era. *Journal of Service Science and Management*, 14(4), 444-460. <https://www.scirp.org/journal/paperinformation?paperid=111198>
- Pramesh, C. S., Badwe, R. A., Bhoo-Pathy, N., Booth, C. M., Chinnaswamy, G., Dare, A. J., ... & Weiderpass, E. (2022). Priorities for cancer research in low-and middle-income countries: a global perspective. *Nature medicine*, 28(4), 649-657. <https://www.nature.com/articles/s41591-022-01738-x>
- Lugada, E., Komakech, H., Ochola, I., Mwebaze, S., Olowo Oteba, M., & Okidi Ladwar, D. (2022). Health supply chain system in Uganda: current issues, structure, performance, and implications for systems strengthening. *Journal of pharmaceutical policy and practice*, 15(1), 14. <https://www.tandfonline.com/doi/abs/10.1186/s40545-022-00412-4>
- Gonçalves, E. (2020). Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment. *The European Journal of Health Economics*, 21(3), 311-320. <https://link.springer.com/article/10.1007/s10198-019-01147-x>

- Ozawa, S., Higgins, C. R., Yemeke, T. T., Nwokike, J. I., Evans, L., Hajjou, M., & Pribluda, V. S. (2020). Importance of medicine quality in achieving universal health coverage. *PLoS One*, *15*(7), e0232966. <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0232966>
- Zhang, Y., Wushouer, H., Han, S., Fu, M., Guan, X., Shi, L., & Wagner, A. (2021). The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. *BMJ Global Health*, *6*(7), e006196. <https://gh.bmj.com/content/6/7/e006196.abstract>
- Orubu, E. S. F., Ching, C., Zaman, M. H., & Wirtz, V. J. (2020). Tackling the blind spot of poor-quality medicines in universal health coverage. *Journal of pharmaceutical policy and practice*, *13*, 1-10. <https://link.springer.com/article/10.1186/s40545-020-00208-4>
- Garattini, S., Natsis, Y., & Banzi, R. (2021). Pharmaceutical strategy for Europe: reflections on public health-driven drug development, regulation, and policies. *Frontiers in pharmacology*, *12*, 685604. <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.685604/full>
- Nazar, R., Meo, M. S., & Ali, S. (2022). Role of public health and trade for achieving sustainable development goals. *Journal of Public Affairs*, *22*(3), e2585. <https://onlinelibrary.wiley.com/doi/abs/10.1002/pa.2585>
- Tao, W., Zeng, Z., Dang, H., Lu, B., Chuong, L., Yue, D., ... & Kominski, G. F. (2020). Towards universal health coverage: lessons from 10 years of healthcare reform in China. *BMJ global health*, *5*(3), e002086. <https://gh.bmj.com/content/5/3/e002086.abstract>
- Galasso, I. (2024). Precision medicine for whom? public health outputs from “Genomics England” and “All of Us” to make up for upstream and downstream exclusion. *The American Journal of Bioethics*, *24*(3), 71-85. <https://www.tandfonline.com/doi/abs/10.1080/15265161.2023.2180108>